Agenus Inc
$ 3.22
4.89%
24 Feb - close price
- Market Cap 110,955,000 USD
- Current Price $ 3.22
- High / Low $ 3.35 / 3.02
- Stock P/E N/A
- Book Value -8.35
- EPS -1.57
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -12.79 %
- 52 Week High 7.34
- 52 Week Low 1.38
About
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$12.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-05 | 2025-03-12 | 2024-11-05 | 2024-08-08 | 2024-05-07 | 2024-03-14 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-14 |
| Reported EPS | 1.94 | -1 | -1.03 | -2.04 | -3.08 | -2.52 | -3.04 | -0.13 | -0.16 | -0.2 | -0.22 | -0.24 |
| Estimated EPS | -0.28 | -0.27 | -1.98 | -2.542 | -2.33 | -1.44 | -3.22 | -0.05 | -0.19 | -0.2 | -0.21 | -0.22 |
| Surprise | 2.22 | -0.73 | 0.95 | 0.502 | -0.75 | -1.08 | 0.18 | -0.08 | 0.03 | 0 | -0.01 | -0.02 |
| Surprise Percentage | 792.8571% | -270.3704% | 47.9798% | 19.7482% | -32.1888% | -75% | 5.5901% | -160% | 15.7895% | 0% | -4.7619% | -9.0909% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGEN
2026-02-19 20:41:34
Agenus Inc. announced new translational data showing that its botensilimab (BOT) and balstilimab (BAL) combination therapy effectively treats "immunologically cold" tumors like MSS colorectal cancer. The research identifies that integrating blood-based inflammatory markers with tumor immune features provides a superior method for predicting patient survival outcomes compared to traditional biomarkers.
2026-02-13 12:27:54
Garo Armen argues that the biopharma regulatory system needs urgent and extensive reform because the old system failed patients by rewarding delay and incrementalism. He contends that while leadership changes at the FDA and HHS are a start, true reform must accelerate patient access to innovative treatments, particularly immunotherapies, which require a different evaluation framework than traditional chemotherapies. Armen emphasizes that for patients with life-threatening diseases, time is critical, and the regulatory process must become faster and more aligned with modern medical science to prevent unnecessary suffering and deaths due to bureaucratic hurdles.
2026-02-10 07:58:28
Agenus Inc. is set to present new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program at the AACR-IO Conference in February 2026. The presentation will detail how systemic and tumor microenvironment inflammation, along with peripheral immune cell states, influence outcomes in patients with immunologically "cold," treatment-refractory tumors treated with BOT alone or in combination with balstilimab (BAL). This research aims to extend immunotherapy benefits to cancers that typically respond poorly to conventional treatments by targeting complementary immune pathways.
2026-02-09 18:28:17
Agenus Inc. (Nasdaq: AGEN) announced that new translational and clinical biomarker data from its botensilimab (BOT) immunotherapy program have been accepted for presentation at the AACR-IO Conference on February 18–21, 2026. The abstract discusses how systemic and tumor microenvironment inflammation, alongside peripheral immune cell states, correlate with clinical outcomes in patients with immunologically cold, treatment-refractory tumors treated with BOT alone or in combination with balstilimab (BAL). BOT and BAL target complementary immune pathways, aiming to expand immunotherapy benefits to cancers that typically respond poorly to standard treatments.
2026-02-05 19:58:28
Agenus Inc. (NASDAQ:AGEN) has received a consensus "Hold" recommendation from brokerages, with an average one-year target price of $14.50. The company recently missed quarterly earnings and revenue expectations, and shares are trading around $2.89 with a market capitalization of approximately $98.3 million. Institutional investors own about 61.46% of the company's stock.
2026-01-27 16:57:22
Agenus discussed its Q2 2025 earnings, highlighting the significant progress of its BOT/BAL immunotherapy, particularly in late-stage microsatellite stable (MSS) colorectal cancer patients, where it demonstrated a 42% two-year survival rate. The company also detailed its upcoming Phase III BATTMAN trial with international collaborators and the strategic advantages from the Zydus manufacturing facility transaction. Additionally, MiNK Therapeutics, an Agenus affiliate, showcased its iNKT cell therapy advancements in both cancer and infectious diseases, emphasizing its non-dilutive government funding and unique clinical benefits.
